Hims & Hers Health (NYSE:HIMS) Trading 2.7% Higher

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report)’s stock price traded up 2.7% during trading on Wednesday . The company traded as high as $25.74 and last traded at $24.79. 11,898,449 shares were traded during trading, a decline of 0% from the average session volume of 11,912,538 shares. The stock had previously closed at $24.15.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Jefferies Financial Group restated a “hold” rating and set a $15.00 target price (down from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Leerink Partnrs restated a “market perform” rating on shares of Hims & Hers Health in a research report on Monday, February 26th. TheStreet upgraded Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. Imperial Capital upgraded Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price objective on the stock in a report on Wednesday, February 28th. Finally, Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.43.

Get Our Latest Stock Report on Hims & Hers Health

Hims & Hers Health Stock Performance

The stock’s 50 day simple moving average is $16.17 and its two-hundred day simple moving average is $12.80. The firm has a market capitalization of $5.32 billion, a PE ratio of -2,479.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMSGet Free Report) last released its earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The business had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. During the same period last year, the company posted ($0.05) EPS. The business’s revenue was up 45.8% on a year-over-year basis. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.19 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95. Following the sale, the insider now owns 166,866 shares of the company’s stock, valued at approximately $2,611,452.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, COO Melissa Baird sold 11,751 shares of Hims & Hers Health stock in a transaction that occurred on Friday, April 5th. The shares were sold at an average price of $14.58, for a total transaction of $171,329.58. Following the sale, the chief operating officer now owns 538,932 shares of the company’s stock, valued at approximately $7,857,628.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95. Following the sale, the insider now directly owns 166,866 shares in the company, valued at approximately $2,611,452.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 880,687 shares of company stock valued at $15,057,669. 17.71% of the stock is currently owned by company insiders.

Institutional Trading of Hims & Hers Health

Several institutional investors have recently added to or reduced their stakes in HIMS. Vanguard Group Inc. lifted its stake in Hims & Hers Health by 1.0% during the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares in the last quarter. Forerunner Ventures Management LLC acquired a new position in Hims & Hers Health during the fourth quarter worth $86,836,000. Dimensional Fund Advisors LP lifted its stake in Hims & Hers Health by 9.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock worth $19,117,000 after purchasing an additional 193,507 shares in the last quarter. Farallon Capital Management LLC lifted its stake in Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after purchasing an additional 1,634,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Hims & Hers Health by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock worth $11,523,000 after purchasing an additional 22,009 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Featured Articles

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.